PET response signals increased survival in soft-tissue sarcoma

Share this content:

Patients with soft-tissue sarcoma (STS) who demonstrate an early pathologic response on positron emission tomography (PET) after the initial cycle of neoadjuvant chemotherapy survive longer than patients showing no such response, according to recent study findings.

Neoadjuvant chemotherapy is associated with considerable toxicity and limited survival benefits in persons with STS. For this study, the researchers sought to learn whether 2[18F]fluoro-2-deoxy-D-glucose (18F-FDG)-PET/computed tomographic (CT) imaging could predict survival in STS patients after an initial cycle of neoadjuvant therapy.

A total of 39 STS patients underwent 18F-FDG-PET/CT imaging to measure tumor metabolism (how much glucose was being taken up by the tumor) before and after the first round of chemotherapy. Persons whose tumors had a reduction in metabolic activity of 25% or more were later determined to have significantly higher survival rates than persons with a tumor-activity reduction of less than 25%. As the investigators noted in Clinical Care Research (2012;18[7]:2024-2031), 7 of 15 early PET nonresponders died during follow-up, compared with only 4 of 24 early PET responders.

The PET response can help clinicians determine quickly whether a person with STS is receiving appropriate chemotherapy.

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs